Schedule of estimated useful lives of property, plant and equipment

The Company's property, plant, and equipment primarily consist of buildings, land, assembly equipment, molding machines, molds, office equipment, furniture, and fixtures. Depreciation and amortization are calculated using the straight-line method over the following useful lives:


Production equipment		3 to 13 years
Office furniture and equipment		3 to 10 years
Buildings		39 years
Building improvements		5 to 15 years

Schedule of disaggregated information of revenue recognized from contracts with customers and licensing fees recognized

Disaggregated information of revenue recognized from contracts with customers and licensing fees recognized are as follows:


	For the three months ended September 30, 2025:
			Blood						Total
			Collection		EasyPoint^®		Other		Product
Geographic Segment	Syringes		Products		Needles		Products		Sales
U.S. sales	$	5,508,018	$	367,681	$	3,303,166	$	8,711	$	9,187,576
North and South America sales (excluding U.S.)		144,326		—		405,472		—		549,798
Other international sales		195,414		5,070		145,116		2,749		348,349
Total	$	5,847,758	$	372,751	$	3,853,754	$	11,460	$	10,085,723


	For the three months ended September 30, 2024:
			Blood						Total
			Collection		EasyPoint^®		Other		Product
Geographic Segment	Syringes		Products		Needles		Products		Sales
U.S. sales	$	4,470,036	$	290,926	$	4,860,327	$	7,319	$	9,628,608
North and South America sales (excluding U.S.)		569,970		—		—		—		569,970
Other international sales		132,817		7,790		3,572		4,100		148,279
Total	$	5,172,823	$	298,716	$	4,863,899	$	11,419	$	10,346,857


	For the nine months ended September 30, 2025:
			Blood						Total
			Collection		EasyPoint^®		Other		Product
Geographic Segment	Syringes		Products		Needles		Products		Sales
U.S. sales	$	16,506,288	$	1,006,343	$	7,570,956	$	25,976	$	25,109,563
North and South America sales (excluding U.S.)		1,670,846		—		1,177,888		—		2,848,734
Other international sales		559,292		13,018		283,724		12,298		868,332
Total	$	18,736,426	$	1,019,361	$	9,032,568	$	38,274	$	28,826,629


	For the nine months ended September 30, 2024:
			Blood						Total
			Collection		EasyPoint^®		Other		Product
Geographic Segment	Syringes		Products		Needles		Products		Sales
U.S. sales	$	14,655,118		991,924	$	5,615,759	$	20,545	$	21,283,346
North and South America sales (excluding U.S.)		1,325,507		96		59,040		6,240		1,390,883
Other international sales		961,429		151,650		178,276		10,000		1,301,355
Total	$	16,942,054	$	1,143,670	$	5,853,075	$	36,785	$	23,975,584

Schedule of diluted EPS under the treasury stock method

The calculation of diluted EPS under the treasury stock method included the following shares in the three and nine month periods ending September 30, 2025 and 2024:


	Three Months Ended		Three Months Ended		Nine Months Ended		Nine Months Ended
	September 30, 2025		September 30, 2024		September 30, 2025		September 30, 2024
Net income (loss)	$	371,047	$	(1,921,989)	$	(10,217,140)	$	(15,657,246)
Preferred stock dividend requirements		(57,611)		(57,611)		(172,833)		(172,832)
Income (loss) applicable to common shareholders	$	313,436	$	(1,979,600)	$	(10,389,973)	$	(15,830,078)
Average common shares outstanding		29,937,159		29,937,159		29,937,159		29,937,159
Average common and common equivalent shares outstanding — diluted		29,937,159		29,937,159		29,937,159		29,937,159
Basic earnings (loss) per share	$	0.01	$	(0.07)	$	(0.35)	$	(0.53)
Diluted earnings (loss) per share	$	0.01	$	(0.07)	$	(0.35)	$	(0.53)